MUC1 and neoplasm: Furthermore, injection of DCs, ex vivo targeted with conjugates of glycan modified tumor antigen MUC1 (oxidized mannan-MUC1), in mice lead to in the generation of high frequencies of MUC1-specific CTL and protection from tumor challenge [63,64].